CVRx Inc
NASDAQ:CVRX
Net Margin
CVRx Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
C
|
CVRx Inc
NASDAQ:CVRX
|
173.2m USD |
-97%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
227.7B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
193.3B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
154.6B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
144.5B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
103.8B USD |
13%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
54.1B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
49.4B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
40.8B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
273.5B CNY |
31%
|
CVRx Inc
Glance View
CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. The company is headquartered in Minneapolis, Minnesota and currently employs 109 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing, manufacturing and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its platform technology offers BAROSTIM, designed to control the brain to address the imbalance of the autonomic nervous system (ANS), which causes heart failure (HF) and other cardiovascular diseases. The Company’s product, BAROSTIM NEO, is a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction (HFrEF). BAROSTIM NEO provides baroreflex activation therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. BAROSTIM NEO consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on CVRx Inc's most recent financial statements, the company has Net Margin of -97.5%.
You don't have any saved screeners yet